Coherus BioSciences Shares Climb 12% on FDA Approval for Cancer Treatment Loqtorzi
Provided by
Dow Jones
By Sabela Ojea
Shares of Coherus BioSciences climbed 12% to $2.96 in after-hours trading after the company said the Food and Drug Administration approved Loqtorzi to treat nasopharyngeal cancer when used with chemotherapy.
The biotechnology company said Friday that Loqtorzi is aimed at patients with metastatic nasopharyngeal cancer.
The FDA backed Loqtorzi, set to be commercially available in the U.S. in the first quarter of 2024, in combination with chemotherapy drugs cisplatin and gemcitabine.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
October 27, 2023 17:40 ET (21:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth